0100495611

open access

Version of Record

Anticancer drug therapy for anaplastic thyroid cancer

English (英語)

European Thyroid Journal

14(2)

e240287

Bioscientifica

2025-04-01

2025-04-21

Online Publication Date: 14 Apr 2025

Anaplastic thyroid cancer is one of the rarest subtypes of thyroid cancer, accounting for only 1–2% of all thyroid cancer cases. It is also one of the most aggressive: prognosis remains dismal and the disease-specific mortality rate is close to 100%. This rarity has markedly limited the availability of prospective trial results, and no standard chemotherapeutic option for unresectable or metastatic anaplastic thyroid cancer has yet been established. Nevertheless, combination therapy with a BRAF inhibitor and MEK inhibitor has shown encouraging efficacy in patients with BRAF V600E-mutated anaplastic thyroid cancer. Other novel treatments such as immune checkpoint inhibitors have also shown promising results. Owing to these therapeutic advances, the prognosis of anaplastic thyroid cancer appears to be gradually improving. However, further development of novel treatments for this rare malignancy requires the development of substantial infrastructure for international collaborative study.

immune checkpoint inhibitor

学術雑誌論文

This work is licensed under a Creative Commons Attribution 4.0 International License.